MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.07
-0.25
-2.68%
After Hours: 9.17 +0.1 +1.10% 19:53 10/26 EDT
OPEN
9.05
PREV CLOSE
9.32
HIGH
9.43
LOW
8.64
VOLUME
2.72M
TURNOVER
--
52 WEEK HIGH
12.68
52 WEEK LOW
1.205
MARKET CAP
226.02M
P/E (TTM)
-41.8165
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What's in the Cards for Cassava (SAVA) This Earnings Season?
Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.
Zacks · 11h ago
Cassava Sciences, Medigus leads healthcare gainers, Neovasc, ProPhase Labs among major losers
Gainers: Cassava Sciences (SAVA) +13%, Medigus (MDGS) +10%, STRATA Skin Sciences (SSKN) +9%, CASI Pharmaceuticals (CASI) +8%, BOQI International Medical (BIMI) +7%.Losers: Neovasc (NVCN) -14%, ProPhase Labs (PRPH) -14%, Milestone Pharmaceuticals (MIST) -13%, Aptose Biosciences (APTO) -9%, Aileron Therapeutics (ALRN) -7%.
Seekingalpha · 3d ago
Mid-Morning Market Update: Markets Mixed; American Express Earnings Miss Estimates
Following the market opening Friday, the Dow traded down 0.01% to 28,363.55 while the NASDAQ fell 0.17% to 11,486.11. However, the S&P rose 0.16% to 3,458.90.
Benzinga · 3d ago
DDD, BCS, CVAC and MAT among premarket gainers
Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaboration with Ultragenyx.Medigus (MDGS) +31% after its subsidiary
Seekingalpha · 3d ago
These Small Caps Are Betting Big On America Losing Its Mind
The following originally appeared on CapitalWatch
Benzinga · 10/19 13:23
We're Not Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. Indeed, Cassava Sciences...
Simply Wall St. · 10/12 20:29
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
Moving Average Crossover Alert: Cassava Sciences
Cassava Sciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zacks · 10/07 12:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAVA. Analyze the recent business situations of Cassava Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAVA stock price target is 14.00 with a high estimate of 16.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 7.82M
% Owned: 31.36%
Shares Outstanding: 24.92M
TypeInstitutionsShares
Increased
17
2.39M
New
35
-1.20M
Decreased
7
1.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Director/President/Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Chief Operating Officer/Director
Nadav Friedmann
Independent Director
Robert Gussin
Independent Director
Michael O' Donnell
Independent Director
Sanford Robertson
Independent Director
Patrick Scannon
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/07/2012
Dividend USD 0.75
12/13/2012
10/25/2010
Dividend USD 2
12/13/2010
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SAVA
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.